[1]
|
FDA “FDA Approves Multaq to Treat Heart Rhythm Disorder,” 2009.
|
[2]
|
T. S. Mohamed Saleem, K. Bharani, C. Madhusudhana Chetty, et al., “Dronedarone in the Management of Atrial Fibrillation,” Open Access Emergency Medicine, Vol. 2010, No. 2, 2010, pp. 17-23. doi:10.2147/OAEM.S8988
|
[3]
|
S. H. Hohnloser, H. J. G. M. Crijns, M. van Eickels, C. Gaudin, R. L. Page, C. Torp-Pedersen and S. J. Connolly, “Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation,” The New England Journal of Medicine, Vol. 360, 2009, pp. 668-678.
|
[4]
|
R. N. Fogoros, “Dronedarone for Atrial Fibrillation, Like Amiodarone But without the Toxicity?” About.com Guide, 2011.
|
[5]
|
N. Penugonda, A. Mohmand-Borkowski and J. F. Burke, “Dronedarone for Atrial Fibrillation: How Does It Compare with Amiodarone?” Cleveland Clinic Journal of Medicine, Vol. 78, No. 3, 2011, pp. 179-185.
|
[6]
|
C. Xie, S. L. Yang, D. F. Zhong, X. J. Dai and X. Y. Chen, “Simultaneous Determination of Dronedarone and Its Active Metabolite Debutyldronedarone in Human Pla- sma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study,” Jour- nal of Chromatography B, Vol. 879, No. 28, 2011, pp. 3071-3075. doi:10.1016/j.jchromb.2011.09.004
|
[7]
|
R. W. Bolderman, J. J. Rob Hermans and J. G. Maessen, “Determination of the Class III Antiarrhythmic Drugs Dronedarone and Amiodarone, and Their Principal Metabolites in Plasma and Myocardium by High-Perfor- mance Liquid Chromatography and UV-Detection,” Journal of Chromatography B, Vol. 877, No. 18-19, 2009, pp. 1727-1731.
|
[8]
|
A. Patel and J. Akhtar, “RP-HPLC Method Development and Validation of Dronedarone HCl in Its Pure Form and Tablet Dosage Form,” Journal of Chemical and Pharmaceutical Research, Vol. 4, No. 4, 2012, pp. 2173-2179.
|
[9]
|
ICH, “Stability Testing of New Drug Substances and Products Q1A (R2),” International Conference on Harmonization, IFPMA, Geneva, 2003.
|
[10]
|
USP, United States Pharmacopoeia, “Validation of Compendial Methods,” 31st Edition, United States Pharmacopeial Convention, Rockville, 2008.
|
[11]
|
J. T. Carstensen and C. T. Rhodes, “Drug Stability Principles and Practices,” 3rd Edition, 2000.
|
[12]
|
M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods—Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.
doi:10.1016/S0731-7085(02)00047-X
|